This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Acute myeloid leukemia targets for bispecific antibodies
Blood Cancer Journal Open Access 03 February 2017
-
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
Blood Cancer Journal Open Access 12 August 2016
-
Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
Blood Cancer Journal Open Access 18 September 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
O’Reilly MK, Paulson JC . Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 2009; 30: 240–248.
Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490–1496.
Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 2010; 33: 599–608.
Baeuerle PA, Kufer P, Bargou R . BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22–30.
von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955–1962.
Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T . Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255–260.
Maccalli C, Scaramuzza S, Parmiani G . TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. Cancer Immunol Immunother 2009; 58: 801–808.
Carmo-Fonseca M, Pfeifer K, Schroder HC, Vaz MF, Fonseca JE, Muller WE et al. Identification of La ribonucleoproteins as a component of interchromatin granules. Exp Cell Res 1989; 185: 73–85.
Acknowledgements
We thank Barbara Uteß, Christine Gräfe, Heidrun Gebauer, Livia Schulze and Martina Franke for excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Drs S Stamova and M Bachmann have applied for patents related to the novel anti-CD33 abs and the novel linker module.
Rights and permissions
About this article
Cite this article
Stamova, S., Cartellieri, M., Feldmann, A. et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 25, 1053–1056 (2011). https://doi.org/10.1038/leu.2011.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.42
This article is cited by
-
Acute myeloid leukemia targets for bispecific antibodies
Blood Cancer Journal (2017)
-
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
Blood Cancer Journal (2016)
-
NK cells and cancer: you can teach innate cells new tricks
Nature Reviews Cancer (2016)
-
Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
Blood Cancer Journal (2015)
-
Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia
Current Hematologic Malignancy Reports (2015)